News

Opinion: The revolutionary sickle cell therapies

todayMarch 21, 2024 11

Background
share close
In December, the FDA approved the first two cell-based gene therapies for treating sickle cell disease: Casgevy and Lyfgenia. And, like any emerging medical technology, the initial use of the innovative gene editing tool has been met with an amalgam of anticipation and anxiety, writes Elizabeth Yuko.

​ In December, the FDA approved the first two cell-based gene therapies for treating sickle cell disease: Casgevy and Lyfgenia. And, like any emerging medical technology, the initial use of the innovative gene editing tool has been met with an amalgam of anticipation and anxiety, writes Elizabeth Yuko. Read More Breaking News, Latest News and Videos | CNN 

Written by:

Rate it